Literature DB >> 29215086

Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome.

Lambertus van den Heuvel1,2,3, Kristian Riesbeck4, Omaima El Tahir5,6, Valentina Gracchi7, Mariann Kremlitzka8, Servaas A Morré5,9, A Marceline van Furth6, Birendra Singh4, Marcin Okrój10, Nicole van de Kar1, Anna M Blom8, Elena Volokhina11,12.   

Abstract

Most cases of hemolytic uremic syndrome (HUS) are caused by infection with enterohemorrhagic Escherichia coli (EHEC). Genetic defects causing uncontrolled complement activation are associated with the more severe atypical HUS (aHUS). Non-EHEC infections can trigger the disease, however, complement defects predisposing to such infections have not yet been studied. We describe a 2-month-old patient infected with different Gram-negative bacterial species resulting in aHUS. Serum analysis revealed slow complement activation kinetics. Rare variant R229C was found in complement inhibitor vitronectin. Recombinant mutated vitronectin showed enhanced complement inhibition in vitro and may have been a predisposing factor for infection. Our work indicates that genetic changes in aHUS can not only result in uncontrolled complement activation but also increase vulnerability to infections contributing to aHUS.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29215086     DOI: 10.1038/s10038-017-0356-0

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  11 in total

1.  Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.

Authors:  I Pela; D Seracini; A Caprioli; F Castelletti; A Giammanco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

2.  Atypical hemolytic uremic syndrome associated with Bordetella pertussis infection.

Authors:  Ignacio Obando; Maria Soledad Camacho; Dolores Falcon-Neyra; Angela Hurtado-Mingo; Olaf Neth
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

3.  Hemolytic uremic syndrome caused by Bordetella pertussis infection.

Authors:  Swasti Chaturvedi; Christoph Licht; Valerie Langlois
Journal:  Pediatr Nephrol       Date:  2010-02-10       Impact factor: 3.714

4.  Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity.

Authors:  Birendra Singh; Anna M Blom; Can Unal; Bo Nilson; Matthias Mörgelin; Kristian Riesbeck
Journal:  Mol Microbiol       Date:  2010-02-19       Impact factor: 3.501

Review 5.  A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.

Authors:  D Westra; J F M Wetzels; E B Volokhina; L P van den Heuvel; N C A J van de Kar
Journal:  Neth J Med       Date:  2012-04       Impact factor: 1.422

Review 6.  Haemolytic uraemic syndrome.

Authors:  Diana Karpman; Sebastian Loos; Ramesh Tati; Ida Arvidsson
Journal:  J Intern Med       Date:  2016-10-10       Impact factor: 8.989

7.  The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly.

Authors:  Astrid Escudero-Esparza; Nikolina Kalchishkova; Emila Kurbasic; Wen G Jiang; Anna M Blom
Journal:  FASEB J       Date:  2013-08-20       Impact factor: 5.191

8.  Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.

Authors:  E B Volokhina; D Westra; T J A M van der Velden; N C A J van de Kar; T E Mollnes; L P van den Heuvel
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

9.  Thrombomodulin mutations in atypical hemolytic-uremic syndrome.

Authors:  Mieke Delvaeye; Marina Noris; Astrid De Vriese; Charles T Esmon; Naomi L Esmon; Gary Ferrell; Jurgen Del-Favero; Stephane Plaisance; Bart Claes; Diether Lambrechts; Carla Zoja; Giuseppe Remuzzi; Edward M Conway
Journal:  N Engl J Med       Date:  2009-07-23       Impact factor: 91.245

10.  Single nucleotide polymorphisms in pathogen recognition receptor genes are associated with susceptibility to meningococcal meningitis in a pediatric cohort.

Authors:  Gijs Th J van Well; Marieke S Sanders; Sander Ouburg; Vinod Kumar; A Marceline van Furth; Servaas A Morré
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more
  2 in total

1.  Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Amy J Osborne; Matteo Breno; Nicolo Ghiringhelli Borsa; Fengxiao Bu; Véronique Frémeaux-Bacchi; Daniel P Gale; Lambertus P van den Heuvel; David Kavanagh; Marina Noris; Sheila Pinto; Pavithra M Rallapalli; Giuseppe Remuzzi; Santiago Rodríguez de Cordoba; Angela Ruiz; Richard J H Smith; Paula Vieira-Martins; Elena Volokhina; Valerie Wilson; Timothy H J Goodship; Stephen J Perkins
Journal:  J Immunol       Date:  2018-03-02       Impact factor: 5.422

2.  Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5.

Authors:  Dennis J Doorduijn; Marie V Lukassen; Marije F L van 't Wout; Vojtech Franc; Maartje Ruyken; Bart W Bardoel; Albert J R Heck; Suzan H M Rooijakkers
Journal:  Elife       Date:  2022-08-10       Impact factor: 8.713

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.